Qingquan Luo, MD, PhD
Shanghai Chest Hospital, Jiao Tong University, Shanghai, China
Dr. Luo was educated in China and received his M.D. degree from Hua Xi Medical University in 1988. He has completed his residency in thoracic surgery and served as a thoracic surgeon in Shanghai Chest Hospital ever since then. In 2005 and 2014, he received his master’s degree in Anatomy from Shanghai Jiao Tong University Medical School and a Ph.D. degree in Oncology from Nanjing Medical University, respectively.
Currently, Dr. Luo is the Surgical Director of the Department of Oncology in the Shanghai Chest Hospital. He is an experienced expert in the field of thoracic surgery and has performed over 10,000 operations since he began working. With a particular focus on minimally invasive treatments for lung tumors, Dr. Luo is a pioneer of video and robot-assisted thoracoscopic surgery. In 2009, he completed the first Da Vinci robot-assisted thoracoscopic surgery (RATS) in mainland China and remained the top thoracic surgeon who has performed the most robotic surgeries (over 1,000 till 2018) in China. He now serves as the Vice President of the Chinese Association for Medical Robots (Chinese Medical Doctor Association), Standing Committee Member for the Experts on Minimally Invasive Thoracic Surgery (Chinese Medical Doctor Association), Leader of the Lung Cancer Academic Group of the Shanghai Anti-Cancer Association, as well as many other academic positions.
His main research interests are the diagnosis and treatment of lung cancer and innovation for minimally invasive surgery, especially robotic techniques. He is the author of over 60 original articles published in both Chinese and English and was awarded a utility model invention patent in 2012. He is currently responsible for several international and domestic projects including projects from the National Health and Technology Development Research Center, the International Cooperation Project of the Ministry of Science and Technology, and the Shanghai Science and Technology Commission Fund.
Terms of Appointment: Feb 2019 - Jan 2021